These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38081808)

  • 1. Mint3-depletion-induced energy stress sensitizes triple-negative breast cancer to chemotherapy via HSF1 inactivation.
    Tanaka N; Okada H; Yamaguchi K; Seki M; Matsubara D; Gotoh N; Suzuki Y; Furukawa Y; Yamashita T; Inoue JI; Kaneko S; Sakamoto T
    Cell Death Dis; 2023 Dec; 14(12):815. PubMed ID: 38081808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANXA2 (annexin A2) is crucial to ATG7-mediated autophagy, leading to tumor aggressiveness in triple-negative breast cancer cells.
    Koh M; Lim H; Jin H; Kim M; Hong Y; Hwang YK; Woo Y; Kim ES; Kim SY; Kim KM; Lim HK; Jung J; Kang S; Park B; Lee HB; Han W; Lee MS; Moon A
    Autophagy; 2024 Mar; 20(3):659-674. PubMed ID: 38290972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1.
    Kanamori A; Matsubara D; Saitoh Y; Fukui Y; Gotoh N; Kaneko S; Seiki M; Murakami Y; Inoue JI; Sakamoto T
    Oncogene; 2020 Sep; 39(39):6218-6230. PubMed ID: 32826949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
    Byerly JH; Port ER; Irie HY
    Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
    Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
    FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
    Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
    Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy.
    Jiang T; Zhu J; Jiang S; Chen Z; Xu P; Gong R; Zhong C; Cheng Y; Sun X; Yi W; Yang J; Zhou W; Cheng Y
    Adv Sci (Weinh); 2023 Jun; 10(17):e2207257. PubMed ID: 37096846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baohuoside I chemosensitises breast cancer to paclitaxel by suppressing extracellular vesicle/CXCL1 signal released from apoptotic cells.
    Wang S; Li J; Xu S; Wang N; Pan B; Yang B; Zheng Y; Zhang J; Peng F; Peng C; Wang Z
    J Extracell Vesicles; 2024 Jul; 13(7):e12493. PubMed ID: 39051750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 regulates paclitaxel resistance in triple negative breast cancers.
    Han J; Yun J; Quan M; Kang W; Jung JG; Heo W; Li S; Lee KJ; Son HY; Kim JH; Choi J; Noh DY; Na D; Ryu HS; Lee C; Kim JI; Moon HG
    J Mol Med (Berl); 2021 Dec; 99(12):1783-1795. PubMed ID: 34626199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR.
    Wang X; Chen T; Li C; Li W; Zhou X; Li Y; Luo D; Zhang N; Chen B; Wang L; Zhao W; Fu S; Yang Q
    J Hematol Oncol; 2022 Aug; 15(1):122. PubMed ID: 36038948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
    Regan Anderson TM; Ma S; Perez Kerkvliet C; Peng Y; Helle TM; Krutilina RI; Raj GV; Cidlowski JA; Ostrander JH; Schwertfeger KL; Seagroves TN; Lange CA
    Mol Cancer Res; 2018 Nov; 16(11):1761-1772. PubMed ID: 29991529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NECAB3 Promotes Activation of Hypoxia-inducible factor-1 during Normoxia and Enhances Tumourigenicity of Cancer Cells.
    Nakaoka HJ; Hara T; Yoshino S; Kanamori A; Matsui Y; Shimamura T; Sato H; Murakami Y; Seiki M; Sakamoto T
    Sci Rep; 2016 Mar; 6():22784. PubMed ID: 26948053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
    Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
    Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
    Lin HY; Kuei CH; Lee HH; Lin CH; Chen YL; Chen CL; Lin YF
    J Mol Med (Berl); 2020 Sep; 98(9):1255-1267. PubMed ID: 32671412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
    Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer.
    Koh SB; Ross K; Isakoff SJ; Melkonjan N; He L; Matissek KJ; Schultz A; Mayer EL; Traina TA; Carey LA; Rugo HS; Liu MC; Stearns V; Langenbucher A; Saladi SV; Ramaswamy S; Lawrence MS; Ellisen LW
    Clin Cancer Res; 2021 Sep; 27(17):4883-4897. PubMed ID: 34168046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.